Company Overview and News

 
D-Street Buzz: Nifty auto outperforms with Ashok Leyland up 5%; HPCL jumps 4%, realty stocks gains

2018-10-12 moneycontrol
Yesterday was the day we want to forget and focus on today as the Indian stock market is witnessing some robust gains with the Nifty50 jumping 157 points, trading at 10,391 while the Sensex has zoomed over 460 points at 34,462.
IOC 500325 533096 532832 533137 DEN GAILF EICHERMOT RLNIY ASHOKLEY TVSMOTOR UNITDSPR 530965 517334 AKLD JSWSTEEL 500182 532432 TATASTEEL TATLY GAILY UQNTY AKLS IBREALEST HINDCOPPER GODREJIND 533150 500228 RELIANCE 533273 533155 JUBLFOOD 505200 532343 MOZTY 500470 RIGD JBLWY HEROMOTOCO 500477 ECQRY HINDALCO 513599 HNDNF OBZIY GODREJPROP TTST OBEROIRLTY MOTHERSUMI HRTQY ADANIPOWER 500164 500440

 
Rate-sensitive stocks end lower after RBI decision

2018-10-05 financialexpress
Shares of interest rate-sensitive stocks ended lower on Friday after the Reserve Bank of India (RBI) kept the benchmark repo rate unchanged at 6.50% during its fourth bi-monthly monetary policy review.
BAJAJ-AUTO INDIANB IDBI 533273 532814 532977 505200 532343 532461 532483 500477 500493 EICHERMOT BHARATFORG ASHOKLEY ECQRY UBNC 500116 TVSMOTOR KMBKY 500877 APOLLOTYRE AYRQY MRZUY AKLD 532401 VIJAYABANK CNRYY 532500 OBZIY PNJZY OBEROIRLTY MARUTI KOTAKBANK PNB 500247 CANBK AKLS

4
Passenger Vehicles in slow lane in H1FY19

2018-10-01 financialexpress
Sales of passenger vehicles in the first-half of FY19 moderated for the country’s top two carmakers, Maruti Suzuki India (MSIL) and Hyundai Motors India (HMIL), with the former growing at 10.5% against 16.6% in the same period last year and the latter seeing a growth of 4.5% against 5.5% last year. The slowdown has come due to a combination of factors which kicked in during the last three months, like a high base effect, floods in several parts of the country affecting demand, and the late onset of the festival season this year.
BAJAJ-AUTO TVSMOTOR 532977 MRZUY AKLD 532500 500182 532343 MARUTI HEROMOTOCO 500477 HRTQY 500570 TATAMOTORS AKLS ASHOKLEY TTM

4
Markets snap 3-day losing streak on liquidity boost; Nifty closes above 11,000

2018-10-01 freepressjournal.in
Mumbai: Equity benchmarks snapped their three-day losing streak Monday as the RBI announced measures to shore up liquidity amid the government pressing for a change of management at the crisis-hit IL&FS. The 30-share BSE Sensex soared 299 points in see-saw trade to close at 36,526.14, while the NSE Nifty jumped 77.85 points to reclaim the 11,000-mark. Positive manufacturing PMI data for September and healthy auto sales numbers also reassured investors, brokers said.
BAJAJ-AUTO 500325 500820 RELIANCE HINDUNILVR 532977 BHRQY ASIANPAINT 533278 532215 505200 532187 AXISBANK RIGD 500696 500477 500570 BHARTIARTL TATAMOTORS EICHERMOT CLNDY RLNIY ASHOKLEY SBAZ YESBANK ECQRY AXB INDUSINDBK KMBKY IBN 532648 YYBKY MRZUY AKLD 532500 AXBKY 532454 AXBA ICICIBANK MARUTI 532174 KOTAKBANK 500247 AKLS COALINDIA TTM

 
Ashok Leyland sales up 26%

2018-10-01 thehindubusinessline
Hinduja Group flagship Ashok Leyland has reported 26 per cent rise in total sales at 19,373 units in September. The company had sold 15,371 units in the same month last year.
500477 AKLS AKLD ASHOKLEY

 
Ashok Leyland sales up 26% at 19,373 units in September

2018-10-01 moneycontrol
Hinduja Group flagship Ashok Leyland Monday reported 26 per cent rise in total sales at 19,373 units in September.
500477 AKLS AKLD ASHOKLEY

 
Ashok Leyland Limited - Press Release

2018-10-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500477 AKLS AKLD ASHOKLEY

4
Motilal Oswal expects moderate two-wheeler, passenger car sales, robust CV growth

2018-09-29 moneycontrol
Caution was the word as auto stocks were under pressure on September 28. Select auto companies even saw fresh short additions on September 27, the expiry day for this month's contracts.
BAJAJ-AUTO ECQRY TVSMOTOR 532977 AKLD 500182 505200 532343 HEROMOTOCO 500477 HRTQY 500570 TATAMOTORS EICHERMOT AKLS ASHOKLEY TTM

4
Auto stocks caught in bear trap, fall 1-8% ahead of September sales data

2018-09-28 moneycontrol
Auto stocks were reeling under selling pressure on Friday especially ahead of their sales data for September which is scheduled to be announced next week.
BAJAJ-AUTO ECQRY TVSMOTOR 532977 AKLD 500182 505200 532343 HEROMOTOCO 500477 HRTQY 500570 TATAMOTORS EICHERMOT AKLS ASHOKLEY TTM

4
Ideas for Profit: Strong financials, attractive valuation make Automotive Axles a long-term buy

2018-09-27 moneycontrol
Automotive Axles (AAL) is a provider of rear drive axle assemblies to commercial vehicles (CV). It caters to all major automobile manufacturers in this space. Market leadership, marquee clientele, operating leverage, lean balance sheet and strong financial performance should support earnings going forward. The business is also gearing itself for the upcoming electric vehicle (EV) wave and trades at reasonable valuations which beckon investor attention.
505010 AUTOAXLES 500477 500570 AKLS TATAMOTORS AKLD TTM ASHOKLEY

 
D-Street Buzz: Over 300 stocks hit fresh 52-week low on NSE; IT gains with Infibeam up 11%, realty stocks bleed

2018-09-24 moneycontrol
It is Monday mayhem on Dalal Street which is witnessing continued bloodbath as the Indian stock market is down 1.5 percent. The Nifty50 is down over 170 points and is trading below the 11,ooo mark while the Sensex is trading lower by 500 points at 36,328.
SWANENERGY TCHQY 532834 532832 532755 535789 532480 CAMLINFIN EICHERMOT CLNDY ASHOKLEY EXIDEIND RELCAPITAL 511072 ALBK JETAIRWAYS YYBKY 517334 AKLD 531213 TECHM DHFL EXQDY TCS COALINDIA AKLS IBREALEST 533271 533150 532617 533273 ASHOKA DELTAMAGNT TTNQY 533278 505200 MOZTY 532540 532187 MANAPPURAM 500477 503100 500111 YESBANK ECQRY PHOENIXLTD INDUSINDBK IDKQY 532648 504286 IBULHSGFIN OBZIY GODREJPROP OBEROIRLTY MOTHERSUMI 500086 503310

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...